Study to Evaluate DNL151 in Subjects With Parkinson's Disease
Completed · Phase 1 · Has a placebo group
Conditions studied: Parkinson's Disease
In brief
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL151 in subjects with Parkinson's disease.
Key facts
- Study ID
- NCT04056689
- Run by
- Biogen
- People needed
- 36
- Starts
- 2019-07-23
- Expected to finish
- 2020-12-02
- Last updated by the study team
- 2023-04-18
Who can join
Age: 30 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- PPD Clinical Research Unit — Orlando, Florida, United States
- Quest Research Institute — Farmington Hills, Michigan, United States
- UZ Leuven — Leuven, Belgium
- Centre for Human Drug Research — Leiden, South Holland, Netherlands
- QPS — Leeuwarden, Netherlands
- Royal Liverpool University Hospital — Liverpool, United Kingdom
- MAC Clinical Research — Manchester, United Kingdom
- Simbec-Orion Clinical Pharmacology — Merthyr Tydfil, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.